RecruitingNCT07114874
Long-term safety of NBI-1117568 in schizophrenia
About this title
Read the official source — NCT07114874Researchers are studying NBI-1117568, tracking side effects to assess long-term safety and tolerability in adults with schizophrenia.
Medication studyAges 18–65Multiple countries
Understand this study
What is this study about?
Researchers are studying NBI-1117568, tracking side effects to assess long-term safety and tolerability in adults with schizophrenia.
Who could participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
What will I do during this study?
Participants receive open-label oral NBI-1117568 once daily for up to 36 months. This is a long-term safety follow-up study.
- Listed locations
- Bryant and 60 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: July 11, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 600
- Sponsor
- Neurocrine Biosciences
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Bulgaria, Romania, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT07114874
- Official title
Show the full official title
A Global, Phase 3, Multicenter, Open-Label Study to Assess the Long-Term Safety and Tolerability of NBI-1117568 in Adults With Schizophrenia
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Bryant, United States · Little Rock, United States · Cerritos, United States
53 more locations
- Chino, United States
- Culver City, United States
- Garden Grove, United States
- La Habra, United States
- Lemon Grove, United States
- Oceanside, United States
- Pico Rivera, United States
- Riverside, United States
- San Diego, United States
- Sherman, United States
- Torrance, United States
- West Hills, United States
- Atlantis, United States
- Aventura, United States
- Doral, United States
- Hollywood, United States
- Maitland, United States
- Miami, United States
- Miami Lakes, United States
- Tampa, United States
- West Palm Beach, United States
- Atlanta, United States
- Decatur, United States
- Peachtree Corners, United States
- Chicago, United States
- Oak Brook, United States
- Gaithersburg, United States
- Boston, United States
- Watertown, United States
- Flowood, United States
- St Louis, United States
- Marlton, United States
- Cedarhurst, United States
- New York, United States
- Staten Island, United States
- The Bronx, United States
- North Canton, United States
- Philadelphia, United States
- Austin, United States
- DeSoto, United States
- Houston, United States
- Orem, United States
- Bellevue, United States
- Pleven, Bulgaria
- Veliko Tarnovo, Bulgaria
- Vratsa, Bulgaria
- San Juan, Puerto Rico
- Brasov, Romania
- Bucharest, Romania
- Sânpetru, Romania
- Belgrade, Serbia
- Gornja Toponica, Serbia
- Kragujevac, Serbia
Interested in joining this study?
Questions about this study
What is this study about?
Researchers are studying NBI-1117568, tracking side effects to assess long-term safety and tolerability in adults with schizophrenia.
Who is behind this study?
The study sponsor is Neurocrine Biosciences, a biotech company.
Does this study involve medication?
Yes. The study involves medication, including NBI-1117568.
Who can participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
Want to explore more studies?
Explore studiesRelated studies
Long-term safety of LB-102 in adults with schizophrenia
A double blind, randomized, placebo-controlled, adaptive 24-week Phase IIb trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia....